Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 3/20 | 0.81 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.81 |
| ▸ | GSK3B | P49841 | 1/20 | 0.72 |
| ▸ | MYC | P01106 | 3/20 | 0.65 |
| ▸ | MAX | P61244 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.62 |
| ▸ | NAT1 | P18440 | 5/20 | 0.58 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194498 | 0.89 | CRHBP (1.00) | CRHBPCRHR2GSK3BMYCMAX | |
| SCHEMBL194499 | 0.89 | CRHBP (1.00) | CRHBPCRHR2GSK3BMYCMAX | |
| SCHEMBL1249353 | 0.89 | CRHBP (1.00) | CRHBPCRHR2GSK3BMYCMAX | |
| SCHEMBL14891688 | 0.85 | CRHBP (0.90) | CRHBPCRHR2GSK3BMYCMAX | |
| SCHEMBL14891689 | 0.85 | CRHBP (0.90) | CRHBPCRHR2GSK3BMYCMAX | |
| SCHEMBL194557 | 0.82 | CRHBP (1.00) | CRHBPCRHR2MYCMAXNPC1 | |
| SCHEMBL194558 | 0.82 | CRHBP (1.00) | CRHBPCRHR2MYCMAXNPC1 | |
| SCHEMBL1249935 | 0.82 | CRHBP (1.00) | CRHBPCRHR2MYCMAXNPC1 | |
| SCHEMBL24992356 | 0.81 | CRHBP (0.71) | CRHBPCRHR2GSK3BMYCMAX | |
| SCHEMBL8173568 | 0.80 | NAT1 (0.75) | CRHBPCRHR2GSK3BMYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2007087424-A2 | METHOD OF TREATING KCNQ RELATED DISORDERS USING ORGANOZINC COMPOUNDS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | CRHBP 4235/4885CRHR2 3191/4885GSK3B 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.